+44 20 8123 2220
info@marketpublishers.com

Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027

https://marketpublishers.com/r/TC6B3B6FA91EN.html
Date: November 2018
Pages: 120
Price: US$ 6,250.00 (Single User License)
ID: TC6B3B6FA91EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2027

+44 20 8123 2220
info@marketpublishers.com

Transthyretin Amyloidosis (ATTR) - Disease Understanding and Treatment Algorithm

Transthyretin (earlier known as prealbumin) is an abundant, soluble, ?-strand rich 55 kDa homotetramer serum protein that is responsible for the transportation of both vitamin A (via retinol-binding protein) and thyroxin throughout the body. TTR is also involved in the binding and redistribution of ?-amyloid in the choroid plexus as well as in the retention of T4 in the cerebral spinal fluid (CSF). TTR may sometimes dissociate into its 127 amino acid monomeric subunits and undergo aberrant changes to form amyloidogenic intermediates. These intermediates then might self-associate to become amyloid fibrils that accumulate as amyloid deposits throughout the body, resulting in Transthyretin Amyloidosis.

Transthyretin Amyloidosis can be sub-classified as wild-type (wt) or hereditary, and the latter is then further sub-divided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).

The DelveInsight Transthyretin Amyloidosis (ATTR) market report gives the thorough understanding of the Transthyretin Amyloidosis (ATTR) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloidosis (ATTR) in the US, Europe, Japan and China.

Transthyretin Amyloidosis (ATTR) Epidemiology

The Transthyretin Amyloidosis (ATTR) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Diagnosed Prevalent Population of ATTR, Type-specific Diagnosed Prevalent Cases and Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy]scenario of Transthyretin Amyloidosis (ATTR) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

+44 20 8123 2220
info@marketpublishers.com

According to DelveInsight, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016 to XXX cases in 2027, growing at a CAGR of XX% during the study period [2016-2027].

DelveInsight also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016.

DelveInsight estimates that the diagnosed prevalent population of ATTR will significantly increase with CAGR of XX % during the study period [2016-2027]

Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and XXX cases of Familial Amyloid Cardiomyopathy in the 7MM

Transthyretin Amyloidosis (ATTR) Drug Chapters

This segment of the Transthyretin Amyloidosis (ATTR) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment options for patients with TTR amyloidosis are limited, with only symptomatic treatment and transplantation. For patients diagnosed with TTR-FAP who have a mild or moderate disease and confirmed by genetic testing and biopsy, a liver transplant is the current standard of care. However, symptomatic treatment is used to provide immediate relief.

Various mechanisms leading to TTR misfolding and fibril formation identified TTR tetramer stabilization as a rate-limiting event, leading to the development of several new pharmacologic therapies for patients with TTR-FAP. These stabilizing agents can be prescribed at an early stage in anticipation of liver transplantation, or, potentially, delaying the need for liver transplant. Drugs use in the treatment of ATTR include- Tafamidis (disease-modifying agent that kinetically stabilizes) and Diflunisal (This drug is an NSAID that stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release and amyloid fibril formation by misfolded TTR monomers).

+44 20 8123 2220
info@marketpublishers.com

Transthyretin Amyloidosis (ATTR) Market Outlook

The Transthyretin Amyloidosis (ATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).

Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR). Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).

Transthyretin Amyloidosis (ATTR) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Transthyretin Amyloidosis (ATTR) Report Insights

Patient Population

+44 20 8123 2220
info@marketpublishers.com

- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Transthyretin Amyloidosis (ATTR) Report Key Strengths

- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Transthyretin Amyloidosis (ATTR) Report Assessment

- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness

+44 20 8123 2220
info@marketpublishers.com

Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Transthyretin Amyloidosis (ATTR) market

Organize sales and marketing efforts by identifying the best opportunities for Transthyretin Amyloidosis (ATTR) market

To understand the future market competition in the Transthyretin Amyloidosis (ATTR) market.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

6. 7MM DIAGNOSED PREVALENT AND SURGERY CASES OF ATTR RELATED CARPAL TUNNEL SYNDROME

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027

Product link: https://marketpublishers.com/r/TC6B3B6FA91EN.html

Price: US$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/TC6B3B6FA91EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com